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مدى انتشار االلتهاب الكبدي الوبائي سي يف مرضى الثالسيميا متعددي نقل 
الدم يف سلطنة عمان
خربة مركز واحد
خالد النعماين، ابراهيم الزكواين، �ضهام ال�ضنانية، فوزية و�ضيم، �ضاهينة داعر
abstract: Objectives: Regular blood transfusions are essential for patients with thalassaemia major. However, 
infections with hepatotropic viruses remain a major concern. The objective of this study was to evaluate the 
prevalence and characteristics of hepatitis C viral (HCV) infection among patients with homozygous beta 
thalassaemia in a single centre in Oman. Methods: A retrospective chart review of 200 patients treated at the 
Thalassemia Unit of Sultan Qaboos University Hospital (SQUH) in Muscat, Oman, between August 1991 and 
December 2011 was performed. Relevant demographic and clinical characteristics were collected, including age, 
gender, HCV status and the presence of endocrinopathies. Results: A total of 81 patients (41%) were found to be 
anti-HCV-antibody (anti-HCV)-positive. HCV ribonucleic acid tests were performed on 65 anti-HCV-positive 
patients and were positive among 33 (51%); the remaining 16 patients died before these tests were available. 
Anti-HCV-positive patients were significantly older than anti-HCV-negative patients (P <0.001) and were more 
likely to be diabetic than anti-HCV-negative patients (27% versus 8%; P <0.001). A total of 100 patients had been 
transfused before they were transferred to SQUH in 1991; of these, 70 (70%) were anti-HCV-positive. Only 11 
(11.5%) of the 96 patients who were seronegative in 1991, or who were transfused later, became seropositive. 
Conclusion: It is likely that the high prevalence of HCV among multi-transfused thalassaemic patients in Oman 
is due to blood transfusions dating from before the implementation of HCV screening in 1991 as the risk of HCV-
associated transfusions has significantly reduced since then. Additionally, results showed that anti-HCV-positive 
patients were more likely to be diabetic than anti-HCV-negative patients. 
Keywords: Hepatitis C; Anti-HCV Antibodies; Beta Thalassemia; Seroprevalence; Blood Transfusions; Blood 
Safety; Oman. 
امللخ�ص: الهدف: نقل الدم املنتظم �رضوري ملر�ضى الثل�ضيميا الكربى.لكن تظل التهابات الكبد الفريو�ضية م�ضدر قلق كبري. الهدف من 
هذه الدرا�ضة هو تقييم مدى انت�ضار االلتهاب الكبدي الوبائي �ضي والتعرف على خ�ضائ�ضه بني املر�ضى الذين يعانون من مر�س الثل�ضيميا 
200 مري�س ممن متت متابعتهم يف وحدة الثل�ضيميا يف م�ضت�ضفى  الطريقة: متت مراجعة ملفات  بيتا يف مركز واحد يف �ضلطنة عمان. 
الدميوغرافية  اخل�ضائ�س  2011. جمعت  دي�ضمرب  و   1991 اأغ�ضط�س  ما بني  الفرتة  �ضلطنة عمان، يف  م�ضقط،  قابو�س يف  ال�ضلطان  جامعة 
 )HCV( وجود اختلل هرموين.النتائج: م�ضادات االأج�ضام �ضد )HCV( وال�رضيرية ذات ال�ضلة، مبا يف ذلك العمر واجلن�س وحالة الفريو�س
 )HCV( يف 65 مري�ضا ممن كانت لديهم م�ضادات االأج�ضام �ضد )RNA( ضد وجدت يف 81 مري�س )%41(. مت فح�س احلم�س النووي�
وكان الفح�س اإيجابيا يف 33 مري�ضا )%51(. تويف 16 مري�ضا قبل اأن تكون هذه االختبارات متوفرة. املر�ضى الذين كانت نتائج م�ضادات 
االأج�ضام لديهم اإيجابية كانوا اأكرب �ضنا بكثري من املر�ضى الذين كانت نتائج م�ضادات االأج�ضام عندهم �ضلبية )P >0.001( وكانوا اأكرث 
عر�ضة لداء ال�ضكري )%27 مقابلP >0.001،8%(. 100 مري�س مت نقل الدم لهم قبل حتويلهم مل�ضت�ضفى جامعة ال�ضلطان قابو�س يف عام 
1991، من هوؤالء 70 )%70( كانت نتائج م�ضادات االأج�ضام �ضد )HCV( اإيجابية. اأحد ع�رض مري�ضا فقط )%11.5( من اأ�ضل 96 مري�ضا 
والذين كانت نتائج م�ضادات االأج�ضام عندهم �ضلبية اأو مت نقل الدم لهم بعد عام 1991 حتولت نتائجهم اإىل اإيجابية. اخلال�صة: من املرجح 
اأن ارتفاع معدل انت�ضار فريو�س التهاب الكبدي الوبائي �ضي بني مر�ضى الثل�ضيميا متعددي نقل الدم يف عمان �ضببه عمليات نقل الدم التي 
يعود تاريخها قبل بدء تنفيذ فح�س )HCV( يف عام 1991 حيث اإنه انخف�س معدل خطر االإ�ضابة بالفريو�س منذ ذلك احلني. باالإ�ضافة 
اإىل اأن النتائج ت�ضري اإىل اأن املر�ضى احلاملني  مل�ضادات االأج�ضام �ضد الفريو�س اأكرث عر�ضة للإ�ضابة بداء ال�ضكري مقارنة باملر�ضى الذين 
ال يحملونها.
مفتاح الكلمات: الكبدي االلتهاب الكبدي الوبائي �ضي؛ االأج�ضام امل�ضادة للفريو�س؛ ثل�ضيميا بيتا؛ االنت�ضار امل�ضلي؛ نقل الدم؛ �ضلمة الدم؛ عمان.
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Homozygous beta thalassaemia (β- thalassaemia) is an inherited anaemia characterised by deficient synthesis of the 
beta globin subunits of the haemoglobin. Oman has 
a high prevalence of thalassaemia in both the beta 
and alpha forms.1 The incidence of homozygous 
β-thalassaemia in Oman is approximately eight in 
10,000, while the global prevalence is reported to be 
around 0.07%.2,3
Regular blood transfusions administered from 
early childhood onwards are the mainstay of 
treatment in β-thalassaemia major patients, while 
thalassaemia intermedia patients only require 
occasional transfusions. Most thalassaemia major 
patients require 2–4 blood transfusions per week 
while those with thalassaemia intermedia can 
usually maintain reasonable haemoglobin levels 
without regular transfusions. However, the latter 
group may occasionally need blood transfusions 
during pregnancy, prior to surgery or if they develop 
an infection. Chronic hepatitis C viral (HCV) 
infections are a comorbidity associated with regular 
blood transfusions; up to 80% of multi-transfused 
thalassaemic patients around the globe are infected 
with transfusion-related viral hepatitis.4–6 Transfusion-
related hepatitis infections are therefore a major 
concern for those with β-thalassaemia.
In addition to the risk of viral hepatitis transmission, 
multiple blood transfusions may lead to iron overload. 
The rate of liver fibrosis reportedly accelerates in 
patients with iron overload and HCV when compared 
to patients with either one alone.7 Zurlo et al. found 
that advanced liver fibrosis is one of the most common 
causes of death in transfusion-dependent thalassaemia 
patients over 15 years old.8 In comparison to the 
previous two decades, recent advances in the 
treatment of thalassaemia, iron overload and HCV 
have led to improved outcomes and survival rates. 
The early identification and treatment of infections 
among thalassaemic patients, before the development 
of advanced fibrosis, can yield better patient responses 
and outcomes.
The prevalence of HCV among multi-transfused 
patients varies from one area to another and depends 
on the endemicity of viral hepatitis in different regions. 
The highest reported prevalence was in Egypt, where 
75% of patients with homozygous β-thalassaemia 
are infected with HCV, while the prevalence ranges 
from 33–67.3% in the neighbouring countries of 
Kuwait and Iraq.9–11
As reported in a study from Iran, the introduction 
of screening blood products for HCV in 1990 led to a 
marked reduction in the incidence of new transfusion-
related chronic HCV cases,12 while the majority of 
currently infected cases are due to infected blood 
products transfused before the implementation of 
screening. Testing for HCV was introduced at Sultan 
Qaboos University Hospital (SQUH) in Muscat, 
Oman, in 1991. This initially began with the first-
generation enzyme-linked immunosorbent assay 
(ELISA); in subsequent years, new generations of both 
the ELISA and recombinant immunoblot assay (RIBA) 
were used as they became commercially available. The 
use of real time-polymerase chain reaction (RT-PCR) 
technology was introduced in 2000.13
The objective of the current study was to evaluate 
the prevalence and characteristics of HCV among 
multi-transfused β-thalassaemia patients in Oman. 
Methods 
This retrospective chart review was conducted 
between August 1991 and December 2011. A total 
of 200 homozygous β-thalassaemia patients treated 
and followed up at the SQUH Thalassemia Unit 
during the study period were evaluated. The SQUH 
Thalassemia Unit is the largest single centre in Oman 
for thalassaemia management. All patients with either 
thalassaemia major (transfusion-dependent; n = 180) 
or thalassaemia intermedia (transfusion-independent; 
Advances in Knowledge 
- The results of this study indicate that the prevalence of hepatitis C viral (HCV) infections in multi-transfused homozygous beta 
thalassaemic patients in Oman is high, especially among older patients. This is likely due to blood transfusions occurring before the 
implementation of HCV screening in 1991.
- This study found that anti-HCV-antibody (anti-HCV)-positive patients were more likely to be diabetic than anti-HCV- 
negative patients. 
Application to Patient Care
- The results of this study support public health efforts to reduce HCV in Oman. National health authorities in Oman can contribute 
to the further reduction of HCV by supporting and recommending advanced blood screening procedures, such as nucleic acid testing. 
Furthermore, promoting endogenous blood donations as well as screening blood products will lead to the further reduction of transfusion-
related HCV among thalassaemic patients in Oman.
- As diabetes is becoming increasingly prevalent in the Omani population, long-term health plans will need to take into account the 
significant correlation between HCV and diabetes found in this study. 
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n = 20) who had been managed in the Thalassemia 
Unit at SQUH from 1991 onwards were included in 
the study. Patients with missing or irretrievable data 
were excluded. Relevant demographic and clinical 
characteristics were collected. 
The following equipment was used to test for 
HCV. In 1991, the first-generation ELISA (Ortho-
Clinical Diagnostics, Inc., Raritan, New Jersey, 
USA) was used to measure anti-HCV antibody. 
Between 1992 and 1996, second-generation enzyme 
immunoassays (Abbott Laboratories, Abbott Park, 
Illinois, USA) were then used. A second-generation 
RIBA (HCV 2.0, Chiron Corp., Emeryville, California, 
USA) was introduced in the SQUH laboratory in 
mid-1994. It was then replaced by third-generation 
RIBAs, the HCV 3.0 (Chiron Corp.) and HCV Blot 
(Genelab Diagnostics Pte. Ltd., Singapore) at the 
end of 1996. Between 1997 and 2001, sera screening 
was performed by a third-generation microparticle 
enzyme immunoassay (AxSYM, Abbott Laboratories). 
Sera that were initially reactive by ELISA were 
retested and the results were interpreted according 
to the manufacturers’ specifications. All sera which 
were repeatedly reactive by ELISA were subjected 
to additional testing by RIBA. HCV ribonucleic acid 
(RNA) was tested on samples using the RT-PCR kit 
COBAS® AMPLICOR HCV Test, Version 2.0 (Roche 
Molecular Systems Inc., Pleasanton, California, 
USA). In 2009, SQUH started testing samples for 
HCV RNA using quantitative COBAS® TaqMan® 
analysers (Roche Molecular Systems Inc.) with a linear 
quantification range between 43 and 6.9 x 107 IU/mL 
and a lower limit of detection of 12.6 IU/mL.
Descriptive statistics were used to present the 
data. For categorical variables, frequencies and 
percentages were reported. Analyses were performed 
using Pearson’s Chi-squared test. For continuous 
variables, means and standard deviations were used to 
summarise the variables while analysis was conducted 
using Student’s t-test. A priori was set at 0.05. Analyses 
were performed using Stata, Version 13.1 (Stata Corp., 
College Station, Texas, USA).
Ethical approval for this study was obtained from 
the Medical Research & Ethics Committee at the 
College of Medicine & Health Sciences, Sultan Qaboos 
University (MREC#402). 
Results
Of the 200 homozygous β-thalassaemia patients 
included in the study, 52.5% were male and the mean 
age was 23 ± 7 years (range: 7–50 years). The majority 
of the patients had thalassaemia major and the rest had 
thalassaemia intermedia [Table 1]. A total of 81 patients 
(41%) were found to be anti-HCV-antibody (anti-
HCV)-positive; including 77 with thalassaemia major 
and four with thalassaemia intermedia. There were 100 
patients (50%) who had been transfused before 1991; 
of these, 70 tested positive for anti-HCV. Additionally, 
11 of 96 patients with thalassaemia major (11.5%) 
who were anti-HCV-negative in 1991, or who started 
transfusions after that date, became seropositive. 
Four patients with thalassaemia intermedia had never 
been transfused. 
Repeat anti-HCV testing using a third-generation 
ELISA confirmed the positive results of the first- 
and second-generation ELISAs. Anti-HCV-positive 
patients were significantly older than their anti-HCV-
negative counterparts (28 versus 20 years; P <0.001) 
and were significantly more likely to be diabetic than 
the anti-HCV-negative patients (27% versus 8%; 
P <0.001). 
No hepatitis B co-infections were noted among 
the patients. Four patients were co-infected with HCV 
and human immunodeficiency virus (HIV). There 
were 41 deaths (20.5%) during the study period; all but 
10 of these patients were infected with HCV. The most 
common causes of death were cardiac complications 
(41%) followed by sepsis (24%). Before HCV RNA 
testing was available, 16 of the 81 patients who tested 
Table 1: Demographic characteristics of homozygous 
beta thalassaemia patients in Oman between 1991 and 
2011 (N = 200)
Characteristics n (%)
Mean age in years 23 ± 7
Male gender 104 (52.5)
Thalassaemia major 180 (90)
Thalassaemia intermedia 20 (10)
HCV infections before 1991 70 (70)
Deaths 41 (20.5)
HCV = hepatitis C virus. Figure 1: Distribution of hepatitis C genotypes among 
homozygous beta thalassaemia patients in Oman 
between 1991 and 2011 (N = 200).
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positive for anti-HCV died; four from HIV-related 
causes, eight from cardiac iron load-related causes and 
four due to bacterial sepsis. Therefore, RT-PCR to detect 
HCV RNA was performed for 65 anti-HCV-positive 
patients. HCV RNA was detected in 33 patients (51%); 
18 (55%) had genotype 1, three (9%) had genotype 2, 
three (9%) had genotype 3 and nine (27%) had genotype 
4 [Figure 1]. Half of these patients had advanced stage 
fibrosis (stages three and four) according to Ludwig et 
al.’s staging system.14 Of the 33 patients with HCV RNA, 
16 (48.5%) underwent a liver biopsy.
The mean serum ferritin level in patients who 
tested positive for anti-HCV was 3,381 ± 3,290 ng/mL 
(normal range: 20–300 ng/mL). Of the 200 patients, 
high liver enzymes were found in 76 (38%). Mean 
alanine aminotransferase levels were significantly 
higher in thalassaemic patients who were positive for 
anti-HCV than in those who were negative (82 ± 111 
versus 46 ± 39 U/L; P = 0.011) and significantly higher 
in those who were HCV RNA-positive than those who 
were HCV RNA-negative (106 ± 150 versus 45 ± 35 
U/L; P = 0.042). 
Discussion
Unlike hepatitis B, there is as yet no vaccination for 
HCV and multi-transfused thalassaemic patients who 
are at high risk of acquiring viral hepatitis.4 There 
has been a marked reduction in transfusion-related 
viral hepatitis worldwide since the implementation 
of screening tests for HCV in the early 1990s.15 As 
observed in a study by Velati et al., transfusion-related 
viral hepatitis cases have also decreased due to the 
introduction of advanced screening methods such as 
nucleic acid testing.16
The current study revealed that 41% of investigated 
β-thalassaemia patients had been infected with HCV. 
This is comparable to the prevalence of anti-HCV 
observed in a similar cohort of patients in Jordan 
(40.5%) but higher than those reported in India (30%), 
Pakistan (35%) and Kuwait (33%).10,17–19 However, 
active HCV infections were found in 33 of the 65 anti-
HCV-positive patients (51%) in the current study who 
could be tested using RT-PCR to detect HCV RNA.
Important factors to keep in mind when evaluating 
the prevalence of HCV in different countries include 
its prevalence in specific populations, the source of 
blood utilised during transfusions, the blood product 
screening methods employed and the age of the cohort 
being studied. There is currently no true population-
based prevalence of HCV in Oman. One study 
reported the seroprevalence of hepatitis C antibodies 
using a second-generation enzyme immunoassay 
which detected antibodies to three HCV antigens in 
26.5% of patients undergoing haemodialysis, 13.4% of 
kidney transplant patients and 1% of non-dialysed non-
transplanted patients with various renal diseases.20 
In another study, Al Dhahry et al. investigated the 
prevalence of HCV among Omani blood donors 
between 1991 and 2001 using three generations of 
ELISAs and RIBAs to confirm positive ELISA tests.13 
Out of 30,012 samples, 272 (0.91%) were positive 
for anti-HCV and 46.5% of these were confirmed 
positive by RIBA, giving a true prevalence of 0.42%. 
The proportion of sera that were confirmed to be anti-
HCV-positive varied from 95% among intravenous 
drug users to 81% in patients with hepatitis and 70% in 
those with haemoglobinopathies.13 
The proportion of positive anti-HCV findings 
among the multi-transfused thalassaemic patients 
in the current study is much higher than the 0.42% 
prevalence reported by Al Dhahry et al.13 It is likely 
that this discrepancy is due to the fact that healthy 
blood donors were used rather than patients with 
thalassaemia. Furthermore, Oman relied on imported 
blood from the USA from the mid-1970s to the 
early 1990s; during this time, the National Health 
and Nutrition Examination Survey III (1988–1994) 
showed HCV to be the most common chronic blood-
borne infection in the USA.21,22 There was also a lack of 
HCV testing for blood products during the specified 
period.22 In addition, the authors of the current study 
observed that many patients travelled to the Indian 
subcontinent for splenectomies in the 1970s and had 
transfusions performed there. In 1984, the screening of 
imported blood for HBV and HIV using HBV surface 
antigen and HIV antigen tests was initiated with the 
help of the World Health Organization.22 In the early 
1990s, the Omani Ministry of Health decided to rely 
on local blood donations to meet the required demand 
and by July 1991 no more imported blood was being 
used in Oman.22
The majority of the thalassaemic patients assessed 
in the current study were infected with HCV before 
the implementation of screening in 1991. This is also 
reflected in the finding that anti-HCV-positive patients 
were significantly older than their counterparts. This is 
in agreement with data from a neighbouring country—
Alavian et al. showed that the pooled odds ratio 
of the HCV infection rate for patients transfused 
before the era of screening in Iran was 7.6 (95% 
confidence interval [CI]: 4.7–12.3).23 The current study 
shows that promoting endogenous blood donation 
and instituting a policy of screening blood products 
has led to a reduction of transfusion-related HCV 
infection in Oman. 
False-positive anti-HCV results have been 
reported with the use of first- and second-generation 
ELISAs.24 However, the patients found to be positive in 
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the present study were tested with a third-generation 
ELISA which confirmed their anti-HCV status. Of 
the anti-HCV-positive patients, 41% had positive 
HCV RNA tests, implying active viral replication. 
More than half were infected with genotype 1. This 
is fitting considering the source of imported blood 
in Oman before 1991, as genotype 1a was common 
in the USA in the early 1990s.25 Genotype 4 was the 
second most common genotype in the current study; 
this genotype is reportedly common in Africa.25 Its 
high prevalence among the studied Omani patients 
is therefore no surprise considering the historical and 
cultural relationship between Oman and East Africa 
and the migratory patterns of many families between 
these two regions. In comparison to other genotypes, 
genotypes 1 and 4 have been associated with a reduced 
response to the combination treatment of pegylated 
interferon and ribavirin.26
One interesting finding of the current study was 
the significant correlation between those who were 
anti-HCV-positive and the presence of diabetes 
mellitus (DM) when compared to anti-HCV-
negative thalassaemic patients. DM is a well-known 
complication of iron overload in multi-transfused 
thalassaemic patients. The worldwide incidence of 
impaired glucose tolerance among thalassaemic 
patients is approximately 4–24% while the incidence 
of DM ranges between 0–26%.27,28 Factors such as 
insulin resistance and insulin deficiency secondary to 
iron deposition in islet cells have been suggested to 
explain the high incidence of DM among thalassaemic 
patients.29 The association between HCV and DM 
has been well-established in the literature.30,31 The 
National Health and Nutrition Examination Survey 
III, which included more than 9,000 subjects aged 
≥20 years, demonstrated that the odds ratio of DM 
developing in anti-HCV-positive subjects ≥40 years 
old is 3.77 (95% CI: 1.80–7.87). This association was 
independent of gender, race and body mass index.32 
The main mechanism that may explain the onset of 
DM in patients with HCV is the development of insulin 
resistance secondary to alterations in the intracellular 
signalling of insulin in such patients.33 The synergic 
effect of HCV and thalassaemia in the development of 
DM has been described in a study by Labropoulou-
Karatza et al.34 Their findings demonstrated that 
thalassaemic patients with HCV were more likely to 
be diabetic compared to thalassaemic patients without 
HCV infections (45.3% versus 11.3%; P <0.001). The 
current study also confirms this association. 
Anti-HCV-positive patients were significantly 
older than their counterparts. However, it is important 
to note that these older patients were poorly chelated 
and thus had significantly higher iron loads. In fact, 
it is likely that the advanced stage fibrosis present in 
a group of relatively young patients (mean age: 28 
years) is secondary to the synergistic effect of HCV 
and iron overload. 
In the current study, four patients were co-infected 
with HCV and HIV. They were born in the early 1980s 
and thus were infected before the implementation of 
blood screening. All of these co-infected patients died 
of HIV-related complications. The main causes of 
death in the study (cardiac complications and sepsis) 
were similar to those reported by Ladis et al. while 
investigating survival rates and causes of death in 
thalassaemic patients from Greece.35 They found that 
heart failure was the most common cause of death 
(71.3%) followed by sepsis (7.8%). Similar results were 
also reported from Italy and Iran.8,36 In the current 
study, 75.6% of the patients who died were infected 
with HCV. This finding affirms the results of previous 
studies describing the morbidity and mortality 
associated with HCV infection in multi-transfused 
thalassaemic patients.37
Conclusion
A total of 200 homozygous β-thalassaemia patients 
were included in the study and 41% were anti-HCV-
positive. Anti-HCV-positive patients were significantly 
more likely to be diabetic than anti-HCV-negative 
patients. In addition, anti-HCV-positive patients were 
significantly older compared to their counterparts. 
This indicates that the high prevalence of HCV among 
multi-transfused thalassaemic patients in Oman is 
likely due to transfusions of HCV-infected blood 
before the implementation of HCV screening in 1991, 
suggesting that blood screening implemented after 
this time has significantly reduced the risk of HCV 
associated with blood transfusions.
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